Apolipoprotein M

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 21-29

  Ren, Kun ^a   Tang, Zhen Li ^a   Jiang, Yue ^a   Tan, Yan Mei ^a   Yi, Guang Hui ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apolipoprotein M; Function; Regulation

Indexed keywords

APOLIPOPROTEIN M; CHOLESTEROL; FARNESOID X RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HIGH DENSITY LIPOPROTEIN; LIVER RECEPTOR HOMOLOG 1; LIVER X RECEPTOR; RETINOID X RECEPTOR; SPHINGOSINE 1 PHOSPHATE; THROMBOCYTE ACTIVATING FACTOR; APOLIPOPROTEIN; APOM PROTEIN, HUMAN; BIOLOGICAL MARKER; LIPOCALIN; LYSOPHOSPHOLIPID; PRE BETA HIGH DENSITY LIPOPROTEIN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; DIABETES MELLITUS; DOWN REGULATION; EX VIVO STUDY; HUMAN; IN VIVO STUDY; INSULIN RELEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES;

ANIMALS; APOLIPOPROTEINS; BIOMARKERS; CARDIOVASCULAR DISEASES; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; LIPOCALINS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; SPHINGOSINE;

EID: 84927653732     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.038     Document Type: Review

References (100)

1. Fisher E.A., Feig J.E., Hewing B., Hazen S.L., Smith J.D. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012, 32:2813-2820.
2. Investigators A.-H., Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
3. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
4. Murphy A.J., Chin-Dusting J.P., Sviridov D., Woollard K.J. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009, 16:667-675.
5. Barter P.J., Brewer H.J., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
6. Xu N., Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999, 274:31286-31290.
7. Pan G., Fu Y., Zuo B., et al. Molecular characterization, expression profile and association analysis with fat deposition traits of the porcine APOM gene. Mol Biol Rep 2010, 37:1363-1371.
8. Flower D.R. The lipocalin protein family: structure and function. Biochem J 1996, 318(Pt 1):1-14.
9. Schlehuber S., Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". Drug Discov Today 2005, 10:23-33.
10. Duan J., Dahlback B., Villoutreix B.O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001, 499:127-132.
11. Ahnstrom J., Faber K., Axler O., Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007, 48:1754-1762.
12. Rosen H., Stevens R.C., Hanson M., Roberts E., Oldstone M.B. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem 2013, 82:637-662.
13. Raper J., Fung R., Ghiso J., Nussenzweig V., Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999, 67:1910-1916.
14. Smith A.B., Esko J.D., Hajduk S.L. Killing of trypanosomes by the human haptoglobin-related protein. Science 1995, 268:284-286.
15. Dalbey R.E., Lively M.O., Bron S., van Dijl J.M. The chemistry and enzymology of the type I signal peptidases. Protein Sci 1997, 6:1129-1138.
16. Axler O., Ahnstrom J., Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008, 582:826-828.
17. Christoffersen C., Ahnstrom J., Axler O., Christensen E.I., Dahlback B., Nielsen L.B. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008, 283:18765-18772.
18. Christoffersen C., Nielsen L.B., Axler O., Andersson A., Johnsen A.H., Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
19. Zhang X.Y., Jiao G.Q., Hurtig M., et al. Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem 2004, 106:123-128.
20. Faber K., Axler O., Dahlback B., Nielsen L.B. Characterization of apoM in normal and genetically modified mice. J Lipid Res 2004, 45:1272-1278.
21. Zhang X.Y., Dong X., Zheng L., et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 2003, 105:67-72.
22. Faber K., Hvidberg V., Moestrup S.K., Dahlback B., Nielsen L.B. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 2006, 20:212-218.
23. Aseem O., Smith B.T., Cooley M.A., et al. Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol 2014, 25:1028-1036.
24. Christensen E.I., Birn H., Storm T., Weyer K., Nielsen R. Endocytic receptors in the renal proximal tubule. Physiology 2012, 27:223-236.
25. Jiao G.Q., Yuan Z.X., Xue Y.S., et al. A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese. Clin Biochem 2007, 40:1108-1112.
26. Niu N., Zhu X., Liu Y., et al. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab Res Rev 2007, 23:21-25.
27. Wu X., Niu N., Brismar K., et al. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin Biochem 2009, 42:17-21.
28. Hu H.J., Jin E.H., Yim S.H., et al. Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis. Exp Mol Med 2011, 43:613-621.
29. Zhou J.W., Tsui S.K., Ng M.C., et al. Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One 2011, 6:e17324.
30. Cao B., Ye Y.Z., Rui J., et al. A single-nucleotide polymorphism in the proximal promoter region of the apolipoprotein M gene is associated with dyslipidaemia but not increased coronary artery diseases in Chinese populations. Lipids Health Dis 2013, 12:184.
31. Zhao D., He Z., Qin X., Li L., Liu F., Deng S. Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population. J Mol Neurosci 2011, 43:370-375.
32. Zhang Y., Mangelsdorf D.J. LuXuRies of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. Mol Interv 2002, 2:78-87.
33. Zhang X., Zhu Z., Luo G., Zheng L., Nilsson-Ehle P., Xu N. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun 2008, 371:114-117.
34. Di D., Wang Z., Liu Y., et al. ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells. Biochem Biophys Res Commun 2012, 421:152-156.
35. Calayir E., Becker T.M., Kratzer A., et al. LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr Pharm Biotechnol 2008, 9:516-521.
36. Houck K.A., Borchert K.M., Hepler C.D., et al. T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 2004, 83:184-187.
37. Seol W., Chung M., Moore D.D. Novel receptor interaction and repression domains in the orphan receptor SHP. Mol Cell Biol 1997, 17:7126-7131.
38. Soodgupta D., Kaul D., Kanwar A.J., Parsad D. Modulation of LXR-alpha and the effector genes by ascorbic acid and statins in psoriatic keratinocytes. Mol Cell Biochem 2014, 397:1-6.
39. Luo G., Feng Y., Zhang J., et al. Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver. Int J Med Sci 2014, 11:1015-1021.
40. Venteclef N., Haroniti A., Tousaint J.J., Talianidis I., Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem 2008, 283:3694-3701.
41. Boulias K., Katrakili N., Bamberg K., Underhill P., Greenfield A., Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 2005, 24:2624-2633.
42. Pare J.F., Malenfant D., Courtemanche C., et al. The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element. J Biol Chem 2004, 279:21206-21216.
43. Clyne C.D., Speed C.J., Zhou J., Simpson E.R. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem 2002, 277:20591-20597.
44. Iwaki M., Matsuda M., Maeda N., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
45. Fayard E., Auwerx J., Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol 2004, 14:250-260.
46. Richter S., Shih D.Q., Pearson E.R., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003, 52:2989-2995.
47. Mosialou I., Krasagakis K., Kardassis D. Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem 2011, 286:17259-17269.
48. Koukos G., Chroni A., Duka A., Kardassis D., Zannis V.I. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Biochem J 2007, 406:167-174.
49. Kuo C.J., Conley P.B., Chen L., Sladek F.M., Darnell J.E., Crabtree G.R. A transcriptional hierarchy involved in mammalian cell-type specification. Nature 1992, 355:457-461.
50. Kritis A.A., Ktistaki E., Barda D., Zannis V.I., Talianidis I. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acids Res 1993, 21:5882-5889.
51. Ktistaki E., Talianidis I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1. Science 1997, 277:109-112.
52. Papamichos-Chronakis M., Petrakis T., Ktistaki E., Topalidou I., Tzamarias D. Cti6, a PHD domain protein, bridges the Cyc8-Tup1 corepressor and the SAGA coactivator to overcome repression at GAL1. Mol Cell 2002, 9:1297-1305.
53. Mosialou I., Zannis V.I., Kardassis D. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem 2010, 285:30719-30730.
54. Zannis V.I., Kan H.Y., Kritis A., Zanni E., Kardassis D. Transcriptional regulation of the human apolipoprotein genes. Front Biosci 2001, 6:D456-D504.
55. Zannis V.I., Kan H.Y., Kritis A., Zanni E.E., Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol 2001, 12:181-207.
56. Sund N.J., Vatamaniuk M.Z., Casey M., et al. Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes Dev 2001, 15:1706-1715.
57. Lee C.S., Friedman J.R., Fulmer J.T., Kaestner K.H. The initiation of liver development is dependent on Foxa transcription factors. Nature 2005, 435:944-947.
58. Wolfrum C., Howell J.J., Ndungo E., Stoffel M. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem 2008, 283:16940-16949.
59. Zhao J.Y., Hu Y.W., Li S.F., et al. Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRalpha expression in HepG2 cells. Lipids Health Dis 2014, 13:50.
60. Ahuja K.D., Ball M.J. Effects of daily ingestion of chilli on serum lipoprotein oxidation in adult men and women. Br J Nutr 2006, 96:239-242.
61. Ahuja K.D., Robertson I.K., Geraghty D.P., Ball M.J. Effects of chili consumption on postprandial glucose, insulin, and energy metabolism. Am J Clin Nutr 2006, 84:63-69.
62. Vigouroux C., Gharakhanian S., Salhi Y., et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999, 25:225-232.
63. de la Brousse F.C., Shan B., Chen J.L. Identification of the promoter of the mouse obese gene. Proc Natl Acad Sci U S A 1996, 93:4096-4101.
64. Xu N., Nilsson-Ehle P., Hurtig M., Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun 2004, 321:916-921.
65. Luo G., Hurtig M., Zhang X., Nilsson-Ehle P., Xu N. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta 1734, 2005:198-202.
66. Tanizawa Y., Okuya S., Ishihara H., Asano T., Yada T., Oka Y. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells. Endocrinology 1997, 138:4513-4516.
67. Zieba D.A., Amstalden M., Maciel M.N., et al. Divergent effects of leptin on luteinizing hormone and insulin secretion are dose dependent. Exp Biol Med 2003, 228:325-330.
68. Kieffer T.J., Heller R.S., Leech C.A., Holz G.G., Habener J.F. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997, 46:1087-1093.
69. Xu N., Zhang X.Y., Dong X., Ekstrom U., Ye Q., Nilsson-Ehle P. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells. Biochem Biophys Res Commun 2002, 292:944-950.
70. Feingold K.R., Shigenaga J.K., Chui L.G., Moser A., Khovidhunkit W., Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199:19-26.
71. Christoffersen C., Pedersen T.X., Gordts P.L., Roebroek A.J., Dahlback B., Nielsen L.B. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ Res 2010, 106:1624-1634.
72. Christoffersen C., Benn M., Christensen P.M., et al. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res 2012, 53:2198-2204.
73. Karuna R., Park R., Othman A., et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011, 219:855-863.
74. Wolfrum C., Poy M.N., Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11:418-422.
75. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283:1839-1847.
76. Mulya A., Seo J., Brown A.L., et al. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res 2010, 51:514-524.
77. Liu M., Seo J., Allegood J., et al. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J Biol Chem 2014, 289:2801-2814.
78. Dullaart R.P., Plomgaard P., de Vries R., Dahlback B., Nielsen L.B. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin Chim Acta 2009, 406:129-133.
79. Axler O., Ahnstrom J., Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48:1772-1780.
80. Elsoe S., Christoffersen C., Luchoomun J., Turner S., Nielsen L.B. Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim Biophys Acta 1831, 2013:1287-1292.
81. Stoffel W., Assmann G. Metabolism of sphingosine bases. XV. Enzymatic degradation of 4t-sphingenine 1-phosphate (sphingosine 1-phosphate) to 2t-hexadecen-1-al and ethanolamine phosphate. Hoppe Seylers Z Physiol Chem 1970, 351:1041-1049.
82. Pappu R., Schwab S.R., Cornelissen I., et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007, 316:295-298.
83. Liu Y., Wada R., Yamashita T., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000, 106:951-961.
84. English D., Welch Z., Kovala A.T., et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000, 14:2255-2265.
85. Ishii I., Fukushima N., Ye X., Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004, 73:321-354.
86. Sevvana M., Ahnstrom J., Egerer-Sieber C., Lange H.A., Dahlback B., Muller Y.A. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393:920-936.
87. Christoffersen C., Obinata H., Kumaraswamy S.B., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 2011, 108:9613-9618.
88. Elsoe S., Ahnstrom J., Christoffersen C., et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221:91-97.
89. Sutter I., Park R., Othman A., et al. Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate. J Lipid Res 2014, 55:1730-1737.
90. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
91. Ahnstrom J., Axler O., Jauhiainen M., et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008, 49:1912-1917.
92. Zhang X., Jiang B., Luo G., Nilsson-Ehle P., Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta 1771, 2007:879-882.
93. Xu N., Nilsson-Ehle P., Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin. Biochem Biophys Res Commun 2006, 342:1174-1177.
94. Cervin C., Axler O., Holmkvist J., et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010, 267:316-321.
95. Plomgaard P., Dullaart R.P., de Vries R., Groen A.K., Dahlback B., Nielsen L.B. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 2009, 266:258-267.
96. Kurano M., Hara M., Tsuneyama K., et al. Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate. Biochim Biophys Acta 1841, 2014:1217-1226.
97. Park Y.J., Yoo S.A., Lee J.H., Chung Y.J., Cho C.S., Kim W. The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia. Clin Exp Rheumatol 2013, 31:180-188.
98. Burger D., Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev 2002, 1:111-117.
99. Singal D.P., Li J., Zhu Y. HLA class III region and susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 2000, 18:485-491.
100. Santos M.J., Fernandes D., Caetano-Lopes J., et al. Lymphotoxin-alpha 252 A>G polymorphism: a link between disease susceptibility and dyslipidemia in rheumatoid arthritis?. J Rheumatol 2011, 38:1244-1249.